EGFR tyrosine kinase inhibitor (TKI) vs observation
Progression‐free survival · maintenance treatment of epithelial ovarian cancer after first‐line chemotherapy
It is very uncertain whether EGFR tyrosine kinase inhibitor (TKI) changes progression‐free survival compared with observation alone (very low certainty).
1 finding from 1 review
- Epidermal growth factor receptor blockers for the treatment of ovarian cancer 2018 · Cochrane Headline outcomes onlyHR 1.05 [0.9, 1.23]1 study · 835 participantsVery low